Sign In
Buy EYEN
$7.56
+0 (+0%)
At Close: Jan 16, 2026
Eyenovia: FDA Setback Is Big Opportunity For Investors
02:03pm, Monday, 08'th Nov 2021
Eyenovia is an under-the-radar ophthalmic company with a large addressable market and big opportunities ahead just received a Complete Response Letter (CRL) from the FDA for its leading drug candidate
CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10
03:25pm, Friday, 05'th Nov 2021
Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be release
Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11
04:05pm, Thursday, 04'th Nov 2021
Company to host an investor conference call and webcast at 5:00pm ET on that day Company to host an investor conference call and webcast at 5:00pm ET on that day
Eyenovia: Can You See Me Now?
01:24pm, Thursday, 21'st Oct 2021
A late-stage biotech company with three products in their pipeline.
Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?
08:00am, Thursday, 30'th Sep 2021
Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.
5 Best Penny Stocks To Buy Right Now According To Insiders
10:53am, Wednesday, 25'th Aug 2021
5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?
09:13am, Thursday, 19'th Aug 2021
Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.
Eyenovia's (EYEN) Management on Q2 2021 Results - Earnings Call Transcript
08:18pm, Wednesday, 11'th Aug 2021
Eyenovia's (EYEN) Management on Q2 2021 Results - Earnings Call Transcript
Eyenovia Reports Second Quarter 2021 Financial Results
04:05pm, Wednesday, 11'th Aug 2021
Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia
Eyenovia to Participate in Two Upcoming Investor Conferences
04:01pm, Wednesday, 07'th Jul 2021
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array p
Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation
06:10am, Wednesday, 02'nd Jun 2021
Eyenovia is a specialty ophthalmic company that I have previously recommended. The company has three drugs in its pipeline - MydCombi, MicroLine, and MicroPine - all using Eyenovia's proprietary Optej
Eyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia Study
11:18am, Tuesday, 25'th May 2021
Eyenovia Inc (NASDAQ: EYEN) has announced topline data from its VISION-1 Phase 3 study evaluating MicroLine, for the temporary improvement of near vision in adults with presbyopia. The results will
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
09:03am, Tuesday, 25'th May 2021
Primary endpoint was achieved with well-tolerated micro-array print (MAP™) safety profile
Eyenovia: Still A Great Long-Term Investment In Ophthalmology
12:43am, Friday, 21'st May 2021
Eyenovia: Still A Great Long-Term Investment In Ophthalmology
Eyenovia's (EYEN) CEO Sean Ianchulev on Q1 2021 Results - Earnings Call Transcript
10:35pm, Wednesday, 12'th May 2021
Eyenovia's (EYEN) CEO Sean Ianchulev on Q1 2021 Results - Earnings Call Transcript
